Clinical evaluation of combination assay of serum tumor markers in non-small-cell lung cancer patients
10.3760/cma.j.issn.1671-7368.2013.11.024
- VernacularTitle:血清肿瘤标志物联合检测对非小细胞肺癌早期诊断的临床价值
- Author:
Ping WANG
;
Yongtong CAO
;
Jinghua LI
;
Tie ZHANG
;
Yuanchun ZHANG
- Publication Type:Journal Article
- Keywords:
Carcinoma,non-small-cell lung;
Early diagnosis
- From:
Chinese Journal of General Practitioners
2013;12(11):921-923
- CountryChina
- Language:Chinese
-
Abstract:
The pre-treatment serum levels of carbohydrate antigen 125 (CA125),cytokeratin 19 fragment 21-1 (CYFRA21-1),squamous carcinoma associated antigen (SCC-Ag),and tissue polypeptide antigen (TPA) were measured in 111 patients with primary non-small-cell lung cancer.And 103 benign lung disease cases and 97 healthy volunteers were also studied as controls.Enzyme linked immunosorbent assay (ELISA) was employed to detect the serum contents of SCC-Ag and TPA.The levels of CA125 and CYFRA21-1 were measured by electrochemical luminescence.The serum level of CYFRA21-1,SCC,TPA and CA125 in cancer patients were significantly higher than those of normal control and benign disease groups (P < 0.01).The combined detection of tumor markers could significantly improve the sensitivity and specificity.And the levels of tumor markers were also correlated with the clinical stages and differentiation degrees.